1800 202 8726
Precancer risk

What Is the Chance — It Becomes Cancer?

You have been told something is abnormal but not yet cancer, and you want to know the actual risk. The answer is not the same for every precancer — it depends on the specific lesion type, its grade, and whether certain risk factors apply to you.

Medically reviewed by Dr. Muralidhar Muddusetty, Surgical Oncologist, MBBS (AIIMS) · MS Surgery (AIIMS) · DNB Surg Onc · MRCS (Edinburgh) · Last reviewed September 2026

  • Lesion type decides the number — The term 'precancer' covers dozens of different findings, each with its own known progression rate.
  • Many never progress — A proportion of precancers — particularly low-grade ones — regress on their own without any treatment.
  • Some risk factors are modifiable — Stopping tobacco or betel nut use, for example, can reduce progression risk for oral precancers.
  • Monitoring is how risk is tracked — Regular follow-up lets your team detect any change early, when treatment options are widest.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

The chance a precancer becomes cancer depends on the specific lesion type, not on precancer as a category. Some findings — particularly low-grade ones — regress without treatment in many people. Others carry a risk that rises over time. Your oncologist can give you the figure that applies to your specific finding.

Why is there no single percentage for all precancers?

The word 'precancer' covers dozens of different findings across different organs, each with its own known progression rate. Using one number for all of them would be inaccurate for every individual one.

NCCN, ASCO, and ESMO each publish guidance on specific lesion types — oral potentially malignant disorders, cervical dysplasia, Barrett's oesophagus, colonic adenomas — and the ranges differ substantially between them.

The relevant question is not 'what percentage of precancers become cancer' but 'what is the progression rate for the specific finding in my report.' Your treating doctor can answer that directly from your pathology result.

What makes a precancer more likely to become cancer?

Continued exposure to what caused the lesion is the factor most consistently linked to progression across lesion types. For oral lesions, that means ongoing tobacco or betel nut use. For cervical lesions, it means persistent high-risk HPV infection.

The grade of the lesion matters. Higher-grade findings carry a greater short-term risk than low-grade ones at the same site. Lesion size and whether it appears in multiple areas also affect the risk your team assigns.

Failure to regress during the monitoring period is a signal in itself. If a lesion that might have been expected to improve has not done so, your team will reassess the approach and may recommend treatment rather than continued observation.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What happens during the monitoring period?

  1. Understanding your specific finding

    Your doctor explains the lesion type, the progression rate that applies to it, and what monitoring involves. This is the appointment to ask for the specific percentage for your result — it varies, and your team has it.

  2. Risk factor review

    Your team identifies which factors apply to you — your exposure history, immune status, lesion grade — and whether any are modifiable. Addressing what can be changed is part of the management, not separate from it.

  3. Baseline investigations

    Depending on the lesion type, this may include a repeat biopsy, imaging, or blood tests. These establish a starting point so future reviews can measure any change against it.

  4. Scheduled follow-up visits

    Reviews happen at defined intervals — more frequent at the start, potentially less frequent if the lesion stays stable. At each visit, your team compares the current picture to the baseline.

  5. Decision at each review

    If the lesion regresses, monitoring may continue or end. If it stays the same or progresses, your team will discuss treatment. You are part of that decision and can ask at each visit what the current picture shows.

How long does progression take, if it happens at all?

For most precancers, progression — when it happens — takes years rather than months. This is one of the properties that makes monitoring a realistic strategy. It gives your team time to detect any change and act on it.

High-grade lesions tend to move faster than low-grade ones at the same site. For some findings, the known risk is considered high enough that treatment is recommended immediately rather than waiting. Your team's decision about monitoring versus treating reflects the pace typical for your lesion type.

We do not yet have reliable ways to predict which individual lesion will progress and which will not. Monitoring is how medicine manages that uncertainty — and catching progression early, when it is most treatable, is the point of it.

Explore 102 more Your Result, What Comes Next and Support topics

HUB — Who Can Have a Biopsy? Special Situations

HUB — Your Biopsy Confirmed Cancer

All Your Result, What Comes Next and Support →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Will my precancer definitely become cancer if I do nothing?

No. Many precancers — particularly low-grade ones — regress on their own without any treatment, and the majority never become cancer at all. What 'doing nothing' means in medicine is monitoring: regular review so your team can detect any change early. The word 'precancer' is a warning to watch closely, not a prediction that cancer is certain. Your team will give you the specific probability for your finding, because that varies widely between lesion types.

How often will I need to come in for follow-up?

The interval depends on the lesion type and grade. Higher-risk findings are typically reviewed more frequently — sometimes every few months. Stable low-grade lesions may need only annual review. Your team sets the schedule based on the known behaviour of your specific lesion type and adjusts it if anything changes. Missing a scheduled review is the situation most likely to allow a change to go undetected, so attend even when you feel well.

If I stop using tobacco or betel nut, does my risk actually go down?

For oral precancers, stopping tobacco and betel nut use is associated with a lower rate of progression in evidence reviewed by WHO and IARC. It does not eliminate risk entirely — the lesion needs to be monitored regardless — but it removes the ongoing driver of damage. The same principle applies to other exposure-related lesions: removing the cause reduces, though does not erase, the risk. Tell your treating team exactly what you use and how much, so they can advise on the evidence for your specific lesion.

What is the difference between a low-grade and a high-grade finding?

Grade describes how much the cells in the lesion differ from normal cells under the microscope. Low-grade cells look close to normal; high-grade cells show more significant changes and are considered to carry a higher short-term progression risk. Grade is one of the main factors your team uses to decide how closely to monitor and whether to recommend treatment rather than observation. It is one piece of the picture alongside lesion type, location, and your individual risk factors — not the whole answer on its own.

Can a treated precancer come back?

Yes. Treatment removes the current lesion but does not necessarily remove the conditions that allowed it to develop. If the underlying cause — tobacco use, HPV infection, sun exposure — continues, a new lesion can form in the same area or nearby. This is why follow-up continues after treatment, and why addressing modifiable risk factors matters beyond the treatment itself. Ask your team what the recurrence rate is for your lesion type and how often you will need to be checked after treatment ends.

When should I ask for a second opinion on a borderline result?

Asking for a second opinion on any result that significantly affects your management is reasonable and normal in oncology. A borderline or 'atypical' finding — one where the pathologist is uncertain about the grade or classification — is exactly the situation where a second pathology review of the tissue can be useful. Ask your treating team to arrange it, or ask for your slides and report to be sent to another centre. A second opinion does not delay treatment for most lesion types, and your team should support the request.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation